Akihiro Uchiike

Itabashi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Comparison of Non-sedating and Sedating Histamine H1-receptor Antagonist Premedication for Preventing Subcutaneous Daratumumab-associated Infusion-related Reactions: A Multicenter Retrospective Observational Study.

Comparison of Non-sedating and Sedating Histamine H1-receptor Antagonist Premedication for Preventing Subcutaneous Daratumumab-associated Infusion-related Reactions: A Multicenter Retrospective Observational Study.

Journal: The Keio journal of medicine

Published: July 15, 2026

Geriatric assessment-based therapy for older patients with diffuse large B-cell lymphoma: results of a two-decade clinical experience.

Geriatric assessment-based therapy for older patients with diffuse large B-cell lymphoma: results of a two-decade clinical experience.

Journal: BMC cancer

Published: January 22, 2026

Contemporary management of diffuse large B-cell lymphoma in Japan.

Contemporary management of diffuse large B-cell lymphoma in Japan.

Journal: Expert review of anticancer therapy

Published: April 07, 2025

Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience.

Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience.

Journal: Journal of pharmaceutical health care and sciences

Published: April 18, 2023

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.

Journal: Journal of pharmaceutical health care and sciences

Published: April 14, 2023

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience.

Journal: Journal of pharmaceutical health care and sciences

Published: October 19, 2022

A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.

A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.

Journal: International journal of clinical pharmacy

Published: September 14, 2021

Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.

Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.

Journal: International journal of clinical pharmacy

Published: January 22, 2018

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.

A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.

Journal: International journal of clinical pharmacy

Published: July 25, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026